Under the agreement, Catalent will use its GPEx technology to develop the cell line for Grid, and perform development activities through to drug manufacturing.
Catalent’s Rob Gustines told us Grid will be responsible for the commercialisation of the mAb.
“Catalent’s role is to support the development of the antibody for Grid Therapeutics, who will determine the future of the programme’s commercialisation,” Gustines told us.
The project – sponsored by Grid – will be undertaken at Catalent’s Madison, Wisconsin-based manufacturing site.
Grid identifies its tumour immunoglobulin G (IgG) antibodies from patients with early stage cancer.
“The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis,” said Grid.
Grid’s lead candidate is the first human derived targeted immunotherapy for cancer.
Last month, Catalent announced it would buy Cook Pharmica to expand its biologics, cell culture manufacturing and packaging capabilities.